Brief: Xspray Posts Q4 Adj. EPS Loss of SEK 2.48
15/02/2023 07:13
Feb 15 (Reuters) - Xspray Q4 adjusted free cash flow SEK -35.003 million. * Q4 pretax profit SEK -55.22 million * Q4 revenue SEK 0
Recent news on Xspray Pharma publ AB
See all newsBrief: Xspray Pharma Gets CRL From FDA
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003